A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05973487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05973487
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Enrollment
- 840 participants
Conditions and interventions
Conditions
- Anogenital Cancers
- Cervical Cancer
- HPV - Anogenital Human Papilloma Virus Infection
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- HPV Positive Rectal Squamous Cell Carcinoma
- HPV-Associated Vaginal Adenocarcinoma
- HPV-Related Adenocarcinoma
- HPV-Related Adenosquamous Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV-Related Endocervical Adenocarcinoma
- HPV-Related Malignancy
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Verrucous Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- Head and Neck Cancer
- Melanoma
- Non-small Cell Carcinoma
- Ovarian Cancer
Interventions
- TSC-200-A0201 Biological
- TSC-200-A0201 + TSC-201-B0702 Biological
- TSC-200-A0201 + TSC-202-A0201 Biological
- TSC-200-A0201 + TSC-203-A0201 Biological
- TSC-200-A0201 + TSC-204-A0101 Biological
- TSC-201-B0702 Biological
- TSC-201-B0702 + TSC-202-A0201 Biological
- TSC-202-A0201 Biological
- TSC-203-A0201 Biological
- TSC-203-A0201 + TSC-201-B0702 Biological
- TSC-203-A0201 + TSC-202-A0201 Biological
- TSC-203-A0201 + TSC-204-A0101 Biological
- TSC-204-A0101 Biological
- TSC-204-A0101 + TSC-202-A0201 Biological
- TSC-204-A0201 Biological
- TSC-204-A0201 + TSC-200-A0201 Biological
- TSC-204-A0201 + TSC-201-B0702 Biological
- TSC-204-A0201 + TSC-202-A0201 Biological
- TSC-204-A0201 + TSC-203-A0201 Biological
- TSC-204-A0201 + TSC-204-A0101 Biological
- TSC-204-A0201 + TSC-204-C0702 Biological
- TSC-204-C0702 Biological
- TSC-204-C0702 + TSC-200-A0201 Biological
- TSC-204-C0702 + TSC-201-B0702 Biological
- TSC-204-C0702 + TSC-202-A0201 Biological
- TSC-204-C0702 + TSC-203-A0201 Biological
- TSC-204-C0702 + TSC-204-A0101 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2024
- Primary completion
- Dec 29, 2026
- Completion
- Dec 29, 2026
- Last update posted
- Nov 16, 2025
2024 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research and Innovation Institute | Scottsdale | Arizona | 85258 | — |
| University of California San Diego | San Diego | California | 92037 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Memorial Healthcare System | Hollywood | Florida | 33021 | — |
| University of Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Orlando Health | Orlando | Florida | 32806 | — |
| University of South Florida | Tampa | Florida | 33606 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Columbia University Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| The Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Providence Cancer Institute Franz Clinic | Portland | Oregon | 97213 | — |
| Allegheny Hospitals Network | Pittsburgh | Pennsylvania | 15224 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05973487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05973487 live on ClinicalTrials.gov.